Nanospectra Biosciences to Present at Texas Life Science Forum
HOUSTON, TX – November 05, 2018 – Nanospectra Biosciences, Inc., a medical device company pioneering a novel use of nanomedicine for selective thermal ablation, today announced that the company has been selected to present at the Texas Life Science Forum on November 8, 2018 at the BioScience Research Collaborative in Houston, Texas. The event, hosted by BioHouston and Rice Alliance for Technology and Entrepreneurship, is the premier life science event in Texas, bringing together members from industry, emerging life science companies, academia and investors.
David Jorden, Nanospectra’s CEO, will present to over 400 attendees. In addition, Nanospectra will participate in the Forum’s ‘Office Hours’ on the preceding day. Office Hours are one-on-one, speed dating type meetings with venture capitalists, corporate innovation groups and angel investors.
“This is a valuable opportunity to update the Texas life science community on the significant milestones that we have achieved over the past year,” said David Jorden, CEO of Nanospectra. “Our commercialization partners are launching products in the United States over the next year using our proprietary nanoshell technology. The Forum will kick off our fund-raising efforts for a financing round that will enable us to advance our own AuroLase® Therapy for prostate cancer tissue ablation through the clinic and on to commercialization.”
About Nanospectra Biosciences
Nanospectra Biosciences is a privately-held medical device company, pioneering the patient-centric use of nanomedicine for selective thermal ablation. AuroLase®, the company’s lead product, is the first ultra-focal therapy for prostate cancer. Nanospectra’s ultra-focal approach maximizes treatment efficacy while minimizing side effects associated with current treatments, including surgery, radiation, and traditional focal therapies. Implementing a multi-prong growth strategy, Nanospectra is focusing on clinical advancements, exclusive partnering agreements and ongoing research and development. Nanospectra’s technology development has been funded to date by a series of grants, private equity investments and corporate partnerships.
For more information visit http://www.nanospectra.com.